chartexchange

CG Oncology drug delivers ‘exceptional’ results in key bladder cancer trial

BioPharma Dive | Nov 16, 2026 12:00 PM EST

CG’s therapy cretostimogene cut the risk of recurrence by 68% when administered after surgery, far surpassing Wall Street’s expectations and lifting company shares. 

Read original article